Introduction Suicidal ideation is common in young people and increases the risk of suicide. Effective interventions that are relevant and accessible to young people, so-called digital natives, are ...
At week 16, 40 of 63 participants receiving ORKA-001 achieved PASI 100, corresponding to complete skin clearance.
Morning Overview on MSN
Veradermics reports late-stage win for hair-loss pill, setting up filing plans
On April 27, 2026, Veradermics, Inc. disclosed that its experimental oral hair-loss drug VDPHL01 hit the primary efficacy ...
Telemonitoring heart failure programmes improved self-care and adherence in a clinical trial. Learn how digital care could ...
BioVersys Announces First Patient First Visit in HABP/VABP Pivotal Phase 3 RIV-TARGET Trial of BV100
BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant ...
Glaukos Corp. (GKOS) announced an update on their ongoing clinical study. Glaukos Corp. (GKOS) is running a Phase 2 trial titled “Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel ...
Introduction Despite its serious impact, anorexia nervosa (AN) remains one of the least understood mental illnesses, with significant gaps in effective treatment options. No medications have been ...
Insilico Medicine ( "Insilico", HKEX:3696 ), a clinical-stage, generative AI–driven drug discovery company, today announced that the inhalation solution of Rentosertib (ISM001-055), the company's ...
A large randomized trial in Germany and Spain found that lowering milk protein intake during the second year of life did not ...
Introduction Gestational diabetes mellitus (GDM) is associated with a high risk of adverse perinatal outcomes. We evaluated ...
Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: ...
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results